CXCL16 in kidney and cardiovascular injury |
| |
| Institution: | 1. Laboratório de Pesquisa em Leishmanioses, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil;2. Grupo de Investigación en Biología Celular y Funcional e Ingeniería de Biomoléculas, Universidad Antonio Nariño, Bogotá, Colombia;3. Grupo de Investigación en Hormonas, Departamento de Química, Universidad Nacional de Colombia, Bogotá, Colombia;4. Facultad de Ciencias, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A.), Bogotá, Colombia;5. Laboratório de Inflamação, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brazil;6. Instituto Leônidas e Maria Deane, FIOCRUZ, Manaus, Brazil;7. Laboratoy for Structural and Computational Proteomics, FIOCRUZ, - Paraná, Brazil |
| |
| Abstract: | CXC chemokine ligand 16 (CXCL16) is a CXC soluble chemokine, an adhesion molecule and a cell surface scavenger receptor. CXCL16 regulates inflammation, tissue injury and fibrosis. Parenchymal renal cells, vascular wall cells, leukocytes and platelets express and/or release CXCL16 under the regulation of inflammatory mediators. CXCL16 expression is increased in experimental and human nephropathies. Targeting CXCL16 protected from experimental glomerular injury or interstitial fibrosis. Conflicting results were reported for experimental cardiovascular injury. High circulating CXCL16 levels are associated to human kidney and cardiovascular disease and urinary CXCL16 may increase in kidney injury. In conclusion, mounting evidence suggests a role of CXCL16 in kidney and cardiovascular disease. However, a better understanding is still required before exploring CXCL16 targeting in the clinic. |
| |
| Keywords: | Atherosclerosis Chemokine Chronic kidney disease Inflammation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
